Dicerna Pharmaceuticals, Inc.
At Dicerna, we create medicines that selectively silence the genes that cause disease using RNA interference, or RNAi. We are leaders in RNAi, harnessing the potential of this powerful and complex process to create medicines that can enhance the health and extend the lives of patients with rare diseases and common diseases with a genetic component.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Clinical Services
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2006
About Us
We go right to the source
Genes play a primary role in thousands of diseases. At Dicerna, we use our proprietary GalXC™ platform to develop safe and potent RNAi therapies that target and suppress genes. We are advancing our growing pipeline of product candidates designed to inhibit the genetic causes of diseases and disorders that affect the liver, kidney, cardiovascular system and central nervous system.
Our team aims to deliver
Dicerna brings together talented experts in biology, chemistry, clinical science, medicine and commercial development. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge, experience and sense of urgency needed to realize the full potential of RNAi technology and expedite the development of breakthrough therapies.
Our purpose is clear: delivering life-changing therapies as efficiently and quickly as possible to help people living with rare diseases and common diseases that have a genetic component.
Our Mission
We interfere with disease
We use RNA interference, or RNAi, to create medicines that silence the genes that cause disease. Our goal is to provide life-changing therapies to people living with rare diseases and common diseases that have a genetic component.